The firm projects that labs-on-a chip and arrays will offer the largest opportunities with nanoparticulate-based solutions also showing significant growth, according to the review. NanoMarkets' new report provides an analysis of drivers, restraints, challenges, regulatory issues and government funding policies that impact nano-enabled drug discovery, along with profiles of the regulatory and funding environments for this kind of technology in 20 major countries.

The report also provides eight-year forecasts that break out the market by key applications segments and product types and it offers profiles of 30 firms already active in this space.

NanoMarkets says that the impact of nano-enabled drug discovery is expected to be both broad and deep, affecting numerous areas of the drug discovery process. The new report predicts that by 2009 19 percent of nano-enabled drug discovery revenues will come from the control and analysis of cells, while another 13 percent will come from DNA/RNA sizing, electropheroresis and quantitation. Genotyping will account for another eleven percent of revenues and high-throughput screening will take another ten percent. Nanotechnology has already enabled new formulations for drugs.

The report goes on to claim that the companies that are in the best position to benefit from the move towards nano-enabled solutions in drug discovery are the major microfluidics and lab-on-chip companies.

NanoMarkets sees opportunities for self-assembly firms in the future because they are offering new solutions, not just for drug discovery, but also for drug delivery and diseases prevention.

MEDICA.de; Source: NanoMarkets